Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Sanofi names its API spin-off Euroapi

by Rick Mullin
January 23, 2021 | A version of this story appeared in Volume 99, Issue 3

 

Sanofi has picked EuroAPI as the name of its active pharmaceutical ingredient (API) manufacturing unit and Karl Rotthier, former CEO of Centrient Pharmaceuticals, as CEO of the business. Positioning EuroAPI as a “made-in-Europe” pharmaceutical services venture, the French drugmaker claims that the unit will be the world’s largest small-molecule API producer and second-largest general API contractor. Sanofi expects EuroAPI to have $1.2 billion in sales in 2022, when it plans a stock offering of the firm.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.